USO 14158

CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Disease Types

Lung Cancer

Available at

BethesdaClintonColumbiaRockvilleSilver SpringWheaton


Cheryl A. Young, RN, BSN
(410) 964-2212 ext 1137